Trials / Completed
CompletedNCT02419417
Study of BMS-986158 in Subjects With Select Advanced Cancers
A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986158 | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2015-06-19
- Primary completion
- 2021-03-17
- Completion
- 2021-03-17
- First posted
- 2015-04-17
- Last updated
- 2022-06-16
- Results posted
- 2022-06-16
Locations
13 sites across 5 countries: United States, Australia, Canada, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02419417. Inclusion in this directory is not an endorsement.